SARS-CoV-2 main protease inhibitors: What is moving in the field of peptides and peptidomimetics?
J Pept Sci
; 29(5): e3467, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: covidwho-2248936
ABSTRACT
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still affecting people worldwide. Despite the good degree of immunological protection achieved through vaccination, there are still severe cases that require effective antivirals. In this sense, two specific pharmaceutical preparations have been marketed already, the RdRp polymerase inhibitor molnupiravir and the main viral protease inhibitor nirmatrelvir (commercialized as Paxlovid, a combination with ritonavir). Nirmatrelvir is a peptidomimetic acting as orally available, covalent, and reversible inhibitor of SARS-CoV-2 main viral protease. The success of this compound has revitalized the search for new peptide and peptidomimetic protease inhibitors. This highlight collects some selected examples among those recently published in the field of SARS-CoV-2.
Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Peptidomiméticos
/
COVID-19
Tópicos:
Vacinas
Limite:
Humanos
Idioma:
Inglês
Revista:
J Pept Sci
Assunto da revista:
Bioquímica
Ano de publicação:
2023
Tipo de documento:
Artigo
País de afiliação:
Psc.3467
Similares
MEDLINE
...
LILACS
LIS